“A highly selective MNK1/MNK2 inhibitor rescues core deficits associated with Fragile X Syndrome” by Tarjani Shukla, a Ph.D. candidate in Molecular and Cell Biology at the University of Texas at Dallas.

Abstract: The behavioral deficits associated with Fragile X syndrome (FXS) are driven by molecular mechanisms that remain largely unknown. We hypothesize that precise control of protein translation with a small molecule inhibitor can resolve key phenotypes present in FXS. This research provides evidence for a potential therapeutic in the context of FXS.

The 20/20 Focus On Research Seminar Series by the University of Texas at Dallas focuses on the outstanding research being conducted at UTD. Faculty and graduate students share the vision of how their projects can make #UTDResearchImpact.